Shield reports completion of recruitment to AEGIS Head to Head Study.

13 Sep 2018

Shield Therapeutics plc, today announces completion of recruitment of the AEGIS–H2H Phase 3b study of oral Feraccru compared to Intravenous (IV) ferric carboxymaltose in subjects with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA).  Feraccru is a novel oral ferric iron therapy that has been approved and marketed in Europe for the treatment of iron deficiency (ID) in adults.

For more information please see the press release below.

Completion of recruitment to AEGIS Head to Head Study 

Back to news

London, UK

120 New Cavendish Street
London
W1W 6XX

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Berlin, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany

t+44 (0) 207 186 8500

einfo@shieldtx.com